Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) nanocomposite particles

Mingshi Yang; Hiromitsu  Yamamoto; Homare  Kurashima; Hirofumi  Takeuchi; Toyokazu  Yokoyama; Hiroyuki  Tsujimoto; Yoshiaki  Kawashima

doi:10.1016/j.ejps.2012.05.016

Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) nanocomposite particles

Mingshi Yang, Hiromitsu Yamamoto, Homare Kurashima, Hirofumi Takeuchi, Toyokazu Yokoyama, Hiroyuki Tsujimoto, Yoshiaki Kawashima

23 Citations (Scopus)

Abstract

The aim of this study was to investigate two types of chitosan-modified poly (dl-lactic-co-glycolic acid) (PLGA) nanocomposite particles containing salmon calcitonin for pulmonary delivery, which were obtained using spray drying fluidized bed granulation (Agglomaster™) and dry powder coating techniques (Mechanofusion™), respectively. The physicochemical properties, pulmonary distribution, pulmonary clearance rate as well as in vivo hypocalcemia actions of the two types of nanocomposite particles were investigated. As indicated by scanning electron micrographs, soft matrix nanocomposite particles and soft ordered nanocomposite particles were produced by Agglomaster™ and Mechanofusion™, respectively. Both forms of chitosan-modified PLGA nanocomposite particles exhibited a high inhalation efficiency, i.e. more than 50% of the two types of nanocomposite particles could be deposited in the deep lung of male Wistar rats. However, the chitosan-modified PLGA nanocomposite particles designed by Agglomaster™ exhibited superior properties to those obtained by Mechanofusion™ with respect to the redispersibility of fine particles in aqueous liquid, the pulmonary retention time and pharmacological effects. In addition, compared with non-modified PLGA nanocomposite particles, the chitosan-modified PLGA nanocomposite particles obtained by Agglomaster™ exhibited enhanced pulmonary absorption of salmon calcitonin via the lung. The findings in this study suggest that the spray drying fluidized bed granulation technique is superior to the dry powder coating technique for producing chitosan-modified dry powder formulations containing salmon calcitonin for inhalation. This can be attributed to the avoidance of aggregation of chitosan-modified PLGA nanocomposite particles when using Agglomaster™ rather than Mechanofusion™.

Original language	English
Journal	European Journal of Pharmaceutical Sciences
Volume	47
Issue number	1
Pages (from-to)	235–243
ISSN	0928-0987
DOIs	https://doi.org/10.1016/j.ejps.2012.05.016
Publication status	Published - 30 Aug 2012

Access to Document

10.1016/j.ejps.2012.05.016

Cite this

@article{e89821d4e05249128adde3c6b85f5fe7,

title = "Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) nanocomposite particles",

abstract = "The aim of this study was to investigate two types of chitosan-modified poly (dl-lactic-co-glycolic acid) (PLGA) nanocomposite particles containing salmon calcitonin for pulmonary delivery, which were obtained using spray drying fluidized bed granulation (Agglomaster{\texttrademark}) and dry powder coating techniques (Mechanofusion{\texttrademark}), respectively. The physicochemical properties, pulmonary distribution, pulmonary clearance rate as well as in vivo hypocalcemia actions of the two types of nanocomposite particles were investigated. As indicated by scanning electron micrographs, soft matrix nanocomposite particles and soft ordered nanocomposite particles were produced by Agglomaster{\texttrademark} and Mechanofusion{\texttrademark}, respectively. Both forms of chitosan-modified PLGA nanocomposite particles exhibited a high inhalation efficiency, i.e. more than 50% of the two types of nanocomposite particles could be deposited in the deep lung of male Wistar rats. However, the chitosan-modified PLGA nanocomposite particles designed by Agglomaster{\texttrademark} exhibited superior properties to those obtained by Mechanofusion{\texttrademark} with respect to the redispersibility of fine particles in aqueous liquid, the pulmonary retention time and pharmacological effects. In addition, compared with non-modified PLGA nanocomposite particles, the chitosan-modified PLGA nanocomposite particles obtained by Agglomaster{\texttrademark} exhibited enhanced pulmonary absorption of salmon calcitonin via the lung. The findings in this study suggest that the spray drying fluidized bed granulation technique is superior to the dry powder coating technique for producing chitosan-modified dry powder formulations containing salmon calcitonin for inhalation. This can be attributed to the avoidance of aggregation of chitosan-modified PLGA nanocomposite particles when using Agglomaster{\texttrademark} rather than Mechanofusion{\texttrademark}.",

author = "Mingshi Yang and Hiromitsu Yamamoto and Homare Kurashima and Hirofumi Takeuchi and Toyokazu Yokoyama and Hiroyuki Tsujimoto and Yoshiaki Kawashima",

year = "2012",

month = aug,

day = "30",

doi = "10.1016/j.ejps.2012.05.016",

language = "English",

volume = "47 ",

pages = "235–243",

journal = "Norvegica Pharmaceutica Acta",

issn = "0928-0987",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) nanocomposite particles

AU - Yang, Mingshi

AU - Yamamoto, Hiromitsu

AU - Kurashima, Homare

AU - Takeuchi, Hirofumi

AU - Yokoyama, Toyokazu

AU - Tsujimoto, Hiroyuki

AU - Kawashima, Yoshiaki

PY - 2012/8/30

Y1 - 2012/8/30

N2 - The aim of this study was to investigate two types of chitosan-modified poly (dl-lactic-co-glycolic acid) (PLGA) nanocomposite particles containing salmon calcitonin for pulmonary delivery, which were obtained using spray drying fluidized bed granulation (Agglomaster™) and dry powder coating techniques (Mechanofusion™), respectively. The physicochemical properties, pulmonary distribution, pulmonary clearance rate as well as in vivo hypocalcemia actions of the two types of nanocomposite particles were investigated. As indicated by scanning electron micrographs, soft matrix nanocomposite particles and soft ordered nanocomposite particles were produced by Agglomaster™ and Mechanofusion™, respectively. Both forms of chitosan-modified PLGA nanocomposite particles exhibited a high inhalation efficiency, i.e. more than 50% of the two types of nanocomposite particles could be deposited in the deep lung of male Wistar rats. However, the chitosan-modified PLGA nanocomposite particles designed by Agglomaster™ exhibited superior properties to those obtained by Mechanofusion™ with respect to the redispersibility of fine particles in aqueous liquid, the pulmonary retention time and pharmacological effects. In addition, compared with non-modified PLGA nanocomposite particles, the chitosan-modified PLGA nanocomposite particles obtained by Agglomaster™ exhibited enhanced pulmonary absorption of salmon calcitonin via the lung. The findings in this study suggest that the spray drying fluidized bed granulation technique is superior to the dry powder coating technique for producing chitosan-modified dry powder formulations containing salmon calcitonin for inhalation. This can be attributed to the avoidance of aggregation of chitosan-modified PLGA nanocomposite particles when using Agglomaster™ rather than Mechanofusion™.

AB - The aim of this study was to investigate two types of chitosan-modified poly (dl-lactic-co-glycolic acid) (PLGA) nanocomposite particles containing salmon calcitonin for pulmonary delivery, which were obtained using spray drying fluidized bed granulation (Agglomaster™) and dry powder coating techniques (Mechanofusion™), respectively. The physicochemical properties, pulmonary distribution, pulmonary clearance rate as well as in vivo hypocalcemia actions of the two types of nanocomposite particles were investigated. As indicated by scanning electron micrographs, soft matrix nanocomposite particles and soft ordered nanocomposite particles were produced by Agglomaster™ and Mechanofusion™, respectively. Both forms of chitosan-modified PLGA nanocomposite particles exhibited a high inhalation efficiency, i.e. more than 50% of the two types of nanocomposite particles could be deposited in the deep lung of male Wistar rats. However, the chitosan-modified PLGA nanocomposite particles designed by Agglomaster™ exhibited superior properties to those obtained by Mechanofusion™ with respect to the redispersibility of fine particles in aqueous liquid, the pulmonary retention time and pharmacological effects. In addition, compared with non-modified PLGA nanocomposite particles, the chitosan-modified PLGA nanocomposite particles obtained by Agglomaster™ exhibited enhanced pulmonary absorption of salmon calcitonin via the lung. The findings in this study suggest that the spray drying fluidized bed granulation technique is superior to the dry powder coating technique for producing chitosan-modified dry powder formulations containing salmon calcitonin for inhalation. This can be attributed to the avoidance of aggregation of chitosan-modified PLGA nanocomposite particles when using Agglomaster™ rather than Mechanofusion™.

U2 - 10.1016/j.ejps.2012.05.016

DO - 10.1016/j.ejps.2012.05.016

M3 - Journal article

C2 - 22683651

SN - 0928-0987

VL - 47

SP - 235

EP - 243

JO - Norvegica Pharmaceutica Acta

JF - Norvegica Pharmaceutica Acta

IS - 1

ER -

Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) nanocomposite particles

Abstract

Access to Document

Fingerprint

Cite this